Aradigm
Latest round
- Series A
Last raised
- Dec 2025
Total raised
- $20M
Investors
- 2
About Aradigm
Aradigm is a specialized biotechnology firm focused on developing innovative drug delivery systems that enhance therapeutic efficacy for chronic respiratory diseases. Their unique formulations aim to improve treatment outcomes for patients. Founded in Hayward, US, Aradigm is dedicated to advancing drug delivery technologies. Aradigm specializes in advanced drug delivery systems designed for chronic respiratory conditions. Their core offerings focus on innovative formulations that improve therapeutic efficacy, catering to the healthcare sector. The products are distributed across North America, Europe, and select Asian markets, serving a diverse clientele ranging from healthcare providers to pharmaceutical companies. Aradigm's revenue model primarily relies on the commercialization of its drug delivery technologies, with clients typically engaging in long-term contracts for product supply.
Who invested in Aradigm
2 investors across 1 round
See all investors in Aradigm
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 9, 2025
Amount
$20M
Investors
Questions about Aradigm
Who invested in Aradigm?
Aradigm has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Aradigm raised?
Aradigm has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Aradigm last raise money?
Aradigm's most recent round on record is a Series A, in Dec 2025.
What does Aradigm do?
Aradigm is a specialized biotechnology firm focused on developing innovative drug delivery systems that enhance therapeutic efficacy for chronic respiratory diseases.
Where is Aradigm headquartered?
Aradigm is headquartered in New York, US.
Which VCs invest in companies like Aradigm?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Aradigm's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Aradigm? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.